Bristol-Myers Squibb Company (BMY) Still Open To Buying Innovative Drugs, Despite Two Failures
1/15/2014 7:12:24 AM
Bristol-Myers Squibb Co. (BMY) will continue to seek out innovative drugs to buy, particularly for cancer, shrugging off two previous deals totaling $7.8 billion in the last three years that failed to pay off for them.
The New York-based drugmaker will target experimental treatments still in development, rather than commercial products that are already on the market, Chief Financial Officer Charles Bancroft said in an interview at the JPMorgan Chase & Co. health-care conference in San Francisco.
Help employers find you! Check out all the jobs and post your resume.
comments powered by